Synta Pharmaceuticals Corporation

Other

Madrigal Pharmaceuticals, Inc.

Kava Pharmaceuticals, Inc.

Prcl Research Inc.

Shoujun Chen

Lijun Sun

Keizo Koya

Jun Jiang

Zhi-Qiang Xia

Mitsunori Ono

Yu Xie

Noriaki Tatsuta

Yaming Wu

Christopher Borella

Weiwen Ying

Takayo Inoue

Junyi Zhang

Hao Li

Gary Bohnert

Zachary Demko

Dinesh U Chimmanamada

Shijie Zhang

Elena Kostik

Guiqing Liang

Zhenjian Du

David James

Farid Vaghefi

Zhiqiang Xia

Kevin Paul Foley

Mei Zhang

Chih-Yi Yu

Nha Huu Vo

Mats Harald Holmqvist

Qinglin Che

Jerome Mahiou

Teresa Kowalczyk-Przewloka

Genliang Lu

Dan Zhou

Stefan M Schweizer

Sami Osman

Dharma Vutukuri

Timothy Korbut

Zhi Qiang Xia

James Loch

Keizo Kova

Joel McCleary

Teresa Kowalczyk Przewloka

The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

Targeted therapeutics

The invention relates to certain compounds or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

Compounds for inflammation and immune-related uses

The invention relates to compounds of structural formula (I) and structural formula (VI): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein R, R, R, Z, L, and n are defined herein. Those compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

The invention relates to compounds of structural formula (I): 

Compounds for the treatment of proliferative disorders

Disclosed are compounds of formulae (I), (III), (IV), (VII), (X), (XI), (XII), (XIII) and (XIV), wherein the variables are as defined in the claims, and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.

Compounds for treating proliferative disorders

Disclosed is a compound represented by the Structural Formula (I):  Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject with cancer by administering to the subject a compound of Structural Formula (I) in combination with Paclitaxel or an analog of Paclitaxel.

Paclitaxel enhancer compounds

Disclosed are compounds and pharmaceutical compositions that are useful for treating a subject with a proliferative disorder, such as cancer. The disclosed compounds and pharmaceutical compositions are also useful for treating disorders responsive to Hsp70 induction and/or natural killer induction.

The invention relates to compounds of structural formula (I) and structural formula (VI): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein R, R, R, Z, L, and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

The invention relates to compounds of structural formula (I) or (II): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein L, L, Y, R, R, R, R, ring A, ring B, ring C, and ring D are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

Substituted fused-ring compounds for inflammation and immune-related uses

The invention relates to compounds of structural formulas (I) and (XVI): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein X, X, Z, L, L, R, R, R, R, n, q, and t are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

Thiophene compounds for inflammation and immune-related uses

Disclosed are compounds of formula (IA), formula (IV) or formula (V), wherein the variables are as defined herein, and pharmaceutical compositions containing them which are useful for treating a subject with a proliferative disorder, such as cancer. The disclosed compounds and pharmaceutical compositions are also useful for treating disorders responsive to Hsp70 induction and/or natural killer induction. 

The invention relates to certain fused ring compounds, or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

Fused ring compounds for inflammation and immune-related uses

The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein Y, L, A, W, W, and R'are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

Substituted aromatic compounds for inflammation and immune-related uses

Growing community of inventors

Bedford, MA, United States of America

Shoujun Chen